Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
Overview of attention for article published in New England Journal of Medicine, July 2026
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
High Attention Score compared to outputs of the same age and source (88th percentile)
Mentioned by
- news
- 20 news outlets
- blogs
- 3 blogs
- 97 X users
- 1 Redditor
- bluesky
- 15 Bluesky users
Readers on
- mendeley
- 58 Mendeley